Mechanisms and management of doxorubicin cardiotoxicity
- 9 June 2011
- journal article
- Published by Springer Science and Business Media LLC in Herz
- Vol. 36 (4), 296-305
- https://doi.org/10.1007/s00059-011-3470-3
Abstract
No abstract availableKeywords
This publication has 135 references indexed in Scilit:
- Mechanisms of Anthracycline Cardiac Injury: Can We Identify Strategies for Cardioprotection?Progress in Cardiovascular Diseases, 2010
- Cardiomyocyte death in doxorubicin-induced cardiotoxicityArchivum Immunologiae et Therapiae Experimentalis, 2009
- Vincristine attenuates doxorubicin cardiotoxicityBiochemical and Biophysical Research Communications, 2008
- Protein quality control and degradation in cardiomyocytesJournal of Molecular and Cellular Cardiology, 2008
- Toll‐like receptor‐4 deficiency attenuates doxorubicin‐induced cardiomyopathy in miceEuropean Journal of Heart Failure, 2008
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 2007
- Dexrazoxane prevents doxorubicin‐induced long‐term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in ratsBritish Journal of Pharmacology, 2007
- Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injuryFree Radical Biology & Medicine, 2007
- Control of Macroautophagy by Calcium, Calmodulin-Dependent Kinase Kinase-β, and Bcl-2Molecular Cell, 2007
- Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor αCell, 2002